期刊
CELL REPORTS
卷 40, 期 6, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.celrep.2022.111177
关键词
-
类别
资金
- Novo Nordisk Foundation [NNF14CC0001]
- European Union [EPIC-XS-823839]
- Acrivon Therapeutics
- JRC-COMBINE (Bayer)
- OncoSignature AB
In this study, the signaling responses of Selinexor in AML patients and cell lines were investigated using phosphoproteomics. The study identified key targetable signaling hubs for rational drug combinations by scoring the phosphorylation sites of P53. Furthermore, combining Selinexor with AKT inhibitor MK-2206 overcame dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects.
Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for AML. To identify the molecular context for monotherapy sensitivity as well as rational drug combinations, we profile selinexor signaling responses using phosphoproteomics in primary AML patient samples and cell lines. Functional phosphosite scoring reveals that p53 function is required for selinexor sensitivity consistent with enhanced efficacy of selinexor in combination with the MDM2 inhibitor nutlin-3a. Moreover, combining selinexor with the AKT inhibitor MK-2206 overcomes dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects. Using high-throughput spatial proteomics to profile subcellular compartments, we measure global proteome and phospho-proteome dynamics, providing direct evidence of nuclear translocation of FOXO3 upon combination treatment. Our data demonstrate the potential of phosphoproteomics and functional phosphorylation site scoring to successfully pinpoint key targetable signaling hubs for rational drug combinations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据